JPWO2019152530A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019152530A5 JPWO2019152530A5 JP2020541924A JP2020541924A JPWO2019152530A5 JP WO2019152530 A5 JPWO2019152530 A5 JP WO2019152530A5 JP 2020541924 A JP2020541924 A JP 2020541924A JP 2020541924 A JP2020541924 A JP 2020541924A JP WO2019152530 A5 JPWO2019152530 A5 JP WO2019152530A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- csf
- cancer
- administered
- prinabrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 29
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 17
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 15
- 238000002360 preparation method Methods 0.000 claims 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 9
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 229960003668 docetaxel Drugs 0.000 claims 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 6
- 108010029961 Filgrastim Proteins 0.000 claims 6
- 208000004235 neutropenia Diseases 0.000 claims 6
- 238000009104 chemotherapy regimen Methods 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 238000002512 chemotherapy Methods 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 229960004679 doxorubicin Drugs 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims 3
- 210000003714 granulocyte Anatomy 0.000 claims 3
- 229960001373 pegfilgrastim Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 229960004177 filgrastim Drugs 0.000 claims 2
- 229940029345 neupogen Drugs 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims 2
- 108010044644 pegfilgrastim Proteins 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 229940007162 zarxio Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023202765A JP2024015120A (ja) | 2018-02-01 | 2023-11-30 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| JP2025234643A JP2026026377A (ja) | 2018-02-01 | 2025-12-05 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625290P | 2018-02-01 | 2018-02-01 | |
| US62/625,290 | 2018-02-01 | ||
| US201862713486P | 2018-08-01 | 2018-08-01 | |
| US62/713,486 | 2018-08-01 | ||
| US201862749060P | 2018-10-22 | 2018-10-22 | |
| US62/749,060 | 2018-10-22 | ||
| US201862757648P | 2018-11-08 | 2018-11-08 | |
| US62/757,648 | 2018-11-08 | ||
| PCT/US2019/015867 WO2019152530A1 (en) | 2018-02-01 | 2019-01-30 | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023202765A Division JP2024015120A (ja) | 2018-02-01 | 2023-11-30 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512121A JP2021512121A (ja) | 2021-05-13 |
| JP2021512121A5 JP2021512121A5 (https=) | 2022-02-08 |
| JPWO2019152530A5 true JPWO2019152530A5 (https=) | 2022-02-08 |
Family
ID=67479904
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541924A Pending JP2021512121A (ja) | 2018-02-01 | 2019-01-30 | プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| JP2023202765A Pending JP2024015120A (ja) | 2018-02-01 | 2023-11-30 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| JP2025234643A Pending JP2026026377A (ja) | 2018-02-01 | 2025-12-05 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023202765A Pending JP2024015120A (ja) | 2018-02-01 | 2023-11-30 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| JP2025234643A Pending JP2026026377A (ja) | 2018-02-01 | 2025-12-05 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210030843A1 (https=) |
| EP (1) | EP3746076A4 (https=) |
| JP (3) | JP2021512121A (https=) |
| KR (2) | KR20200116477A (https=) |
| CN (1) | CN112105363A (https=) |
| AU (1) | AU2019216305B2 (https=) |
| BR (1) | BR112020015758A2 (https=) |
| CA (1) | CA3089391A1 (https=) |
| IL (1) | IL276197A (https=) |
| SG (1) | SG11202006990TA (https=) |
| WO (1) | WO2019152530A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
| EP4045046A4 (en) * | 2019-10-15 | 2024-01-10 | Beyondspring Pharmaceuticals Inc. | Methods and compositions for treating iron disorders |
| JP2023505506A (ja) * | 2019-12-05 | 2023-02-09 | ハンミ ファーマシューティカルズ カンパニー リミテッド | 化学療法または放射線療法で誘導された好中球減少症を治療する方法 |
| CA3186416A1 (en) * | 2020-07-17 | 2022-01-20 | John A. Barrett | Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| FI131561B1 (en) * | 2023-12-28 | 2025-06-30 | Faron Pharmaceuticals Oy | CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
| CN119371407A (zh) * | 2024-06-27 | 2025-01-28 | 青岛海合生物科技有限公司 | 一种具有抗肿瘤功效的2,5-二酮哌嗪类化合物及其在制备治疗和/或预防中性粒细胞减少症的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110132327A (ko) * | 2009-01-16 | 2011-12-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 재조합 인간 알부민-인간 과립구 콜로니 자극 인자 융합 단백질의 신규 안정한 제형 |
| JP6411523B2 (ja) * | 2013-10-11 | 2018-10-24 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| RU2760348C2 (ru) * | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| BR112019015974A2 (pt) * | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
-
2019
- 2019-01-30 KR KR1020207024515A patent/KR20200116477A/ko not_active Ceased
- 2019-01-30 CA CA3089391A patent/CA3089391A1/en active Pending
- 2019-01-30 BR BR112020015758-9A patent/BR112020015758A2/pt unknown
- 2019-01-30 US US16/966,156 patent/US20210030843A1/en active Pending
- 2019-01-30 CN CN201980018772.9A patent/CN112105363A/zh active Pending
- 2019-01-30 SG SG11202006990TA patent/SG11202006990TA/en unknown
- 2019-01-30 JP JP2020541924A patent/JP2021512121A/ja active Pending
- 2019-01-30 KR KR1020267003258A patent/KR20260023097A/ko active Pending
- 2019-01-30 AU AU2019216305A patent/AU2019216305B2/en active Active
- 2019-01-30 WO PCT/US2019/015867 patent/WO2019152530A1/en not_active Ceased
- 2019-01-30 EP EP19746727.7A patent/EP3746076A4/en active Pending
-
2020
- 2020-07-21 IL IL276197A patent/IL276197A/en unknown
-
2023
- 2023-11-30 JP JP2023202765A patent/JP2024015120A/ja active Pending
-
2025
- 2025-12-05 JP JP2025234643A patent/JP2026026377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512121A5 (https=) | ||
| JPWO2019152530A5 (https=) | ||
| JP2024015120A5 (https=) | ||
| Ayash et al. | Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. | |
| Rosen et al. | Chemotherapy for mycosis fungoides and the Sezary syndrome | |
| KR101848131B1 (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| JP2013543879A (ja) | 急性骨髄性白血病を治療するための単独またはシタラビンとの組合せにおけるボラセルチブ | |
| Abeloff et al. | Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer | |
| KR20100054210A (ko) | 암 치료를 위한 육산화사비소의 병용요법 | |
| JPWO2019147615A5 (https=) | ||
| TW202011948A (zh) | 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑 | |
| JP5976923B2 (ja) | イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| SA94140746B1 (ar) | مركب علاجي من /tamoxifen cisplatin للسرطانات في الانسان | |
| WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
| RU2284818C2 (ru) | Комбинированная химиотерапия | |
| JP6458007B2 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| CA3135916C (en) | COMBINED USE OF THE COMPOUND MEDICINE A-NOR-5A ANDROSTANE AND AN ANTI-CANCER MEDICINE | |
| Göksel et al. | Single-agent oral etoposide in patients with relapsed or refractory extensive small-cell lung cancer | |
| Kanat et al. | Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma | |
| Rossi et al. | Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase 2 study | |
| Jett et al. | Chemotherapy for malignant mesothelioma: CAMEO | |
| CN111388665B (zh) | 一种治疗肿瘤的复合物及其制剂和用途 | |
| Natale | Chemotherapy in small cell lung cancer: the current state of the art | |
| Brack et al. | Application for the Inclusion of Vinorelbine for the Treatment of Rhabdomyosarcoma as first line treatment on the WHO Essential Medicines List for Children 2021 | |
| Rades et al. | Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis |